Jupiter Neurosciences Secures $20 Million in Flexible Financing for Parkinson's Trial and Nugevia Product Line Growth

Jupiter Neurosciences has entered into agreements with Yorkville Advisors Global for up to $20 million in flexible financing. The funding will support a Phase 2 Parkinson's trial and accelerate growth of the Nugevia product line. The financing includes a $6 million pre-paid advance and an additional $14 million available under a standby equity purchase agreement. Proceeds will be used to support clinical trials, marketing, and working capital.